Novo Nordisk Taps Anthropic’s Claude to Speed Drug Discovery

The article reports that Novo Nordisk and Anthropic announced a collaboration on September 16, 2026. Under the arrangement, the drugmaker will use Anthropic's frontier AI models. Novo Nordisk will also test the Claude Science workbench in specific research and development workflows, according to the article. The title frames the announcement as Novo Nordisk tapping Anthropic's Claude to speed drug discovery.

The article quotes Dario Amodei, who said the collaboration is built to give leading researchers access to frontier models. Amodei also said that AI's increasing capability could compress a century's worth of biological and medical breakthroughs into a decade. The excerpt does not state whether Amodei was speaking at an event, in a press release, or in an interview. The excerpt identifies no further named participants, and it does not attribute any other statement to a company representative. No financial terms are given.

The excerpt does not state which of Anthropic's models Novo Nordisk will use, nor which research and development workflows will be tested, nor the duration of the collaboration. It does not say how the Claude Science workbench differs from the models described alongside it. The article is published by unite.ai and dated to the announcement of September 16, 2026. The excerpt supplied does not include a response from either company to questions about the arrangement, and it states no figures for cost, headcount, or expected timelines beyond Amodei's characterisation of a century compressed into a decade.